- Home
- VEEA vs PLRX Comparison
VEEA vs PLRX Comparison
Compare VEEA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEA
- PLRX
- Stock Information
- Founded
- VEEA 2014
- PLRX 2015
- Country
- VEEA United States
- PLRX United States
- Employees
- VEEA N/A
- PLRX N/A
- Industry
- VEEA
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- VEEA
- PLRX Health Care
- Exchange
- VEEA NYSE
- PLRX Nasdaq
- Market Cap
- VEEA 83.9M
- PLRX 77.3M
- IPO Year
- VEEA N/A
- PLRX 2020
- Fundamental
- Price
- VEEA $1.68
- PLRX $1.40
- Analyst Decision
- VEEA
- PLRX Hold
- Analyst Count
- VEEA 0
- PLRX 10
- Target Price
- VEEA N/A
- PLRX $9.79
- AVG Volume (30 Days)
- VEEA 29.4K
- PLRX 1.6M
- Earning Date
- VEEA 08-23-2025
- PLRX 08-06-2025
- Dividend Yield
- VEEA N/A
- PLRX N/A
- EPS Growth
- VEEA N/A
- PLRX N/A
- EPS
- VEEA N/A
- PLRX N/A
- Revenue
- VEEA $139,252.00
- PLRX N/A
- Revenue This Year
- VEEA N/A
- PLRX N/A
- Revenue Next Year
- VEEA N/A
- PLRX N/A
- P/E Ratio
- VEEA N/A
- PLRX N/A
- Revenue Growth
- VEEA N/A
- PLRX N/A
- 52 Week Low
- VEEA $1.33
- PLRX $1.10
- 52 Week High
- VEEA $18.56
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- VEEA N/A
- PLRX 54.68
- Support Level
- VEEA N/A
- PLRX $1.13
- Resistance Level
- VEEA N/A
- PLRX $1.27
- Average True Range (ATR)
- VEEA 0.00
- PLRX 0.11
- MACD
- VEEA 0.00
- PLRX 0.02
- Stochastic Oscillator
- VEEA 0.00
- PLRX 90.00
About VEEA VEEA INC
Veea Inc is a company providing an edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. The company has first-in-class VeeaHub smart connectivity and computing hubs that integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.